Registration Options

Register for the meeting.

Session Time and Location

Date: Monday, 04/25/2022

Time: 1:45 PM (view in the schedule)

Room: TBD

Target Audience

If you are a pharmacist, nurse practitioner or other healthcare professional involved in the comprehensive medication management of psychiatric and/or neurological patients, we invite you to participate in this online course.

Session Summary

There is growing focus on use of pharmacogenomic (PGx) testing in the practice of medicine and pharmacy. One company website suggests sales of over 1,500,000 tests. The value it offers within psychiatry remains unclear in certain regards. Current guidelines offer recommendations when PGx results are available but does not provide advice on when or to whom testing may be beneficial. There is also an abundance of PGx testing options available with substantial heterogeneity in terms of clinical validity and utility. In this session, participants will explore different opinions on when to consider ordering PGx testing, what and how to test, as well as strengths and limitations on published clinical studies of PGx guided medication treatment for major depressive disorder.

Faculty Information and Disclosures

Christina Aquilante, PharmD, FCCP

View biographical information and disclosures

Learning Objectives

  1. Recognize strengths and limitations of published clinical studies of pharmacogenomic (PGx) guided medication treatment of major depressive disorder (MDD).
  2. Describe considerations for when or whether PGx testing is warranted.
  3. Review the advantages and disadvantages of using multi-gene compared to single-gene PGx testing panels.
  4. Illustrate how to effectively integrate clinical PGx test results into the electronic health record to maximize use of the information for MDD.

Continuing Education Credit and Disclosures

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.